Abstract
Market Overview
The U.S. infectious disease diagnostics market will play a significant role in
the dynamic IVD market. This market is segmented according to molecular,
immunoassays, and culture infectious disease products. Total market revenues
for base year 2005 are $3,823.1 with a CAGR of 7.7%. The most substantial
growth is expected in the molecular segment. The U.S. infectious disease
diagnostics market is highly competitive and saturated
Tremendous growth opportunities exist in the U.S. infectious disease in-vitro
diagnostics market. High growth areas include viral load testing, nosocomial
infection screening, rapid influenza detection, and STD testing.
Rapid detection and fast turn-around time (TAT) are able to lower total
overall healthcare costs. Quick TAT is especially relevant to infectious
disease testing, as fast diagnosis increases treatment options and patient
prognosis.
Technical superiority of molecular methods is phasing out other types or more
traditional methods, such as culture based tests, which have TATs of only days
and are labor intensive.
View Cart
